Acne, melasma, rosacea, pigmentation, hair loss, and dermatologic conditions.
Icotrokinra (Icotyde) is a once-daily tablet that blocks the IL-23 receptor. What the phase 3 trials, the US label and the labels of other psoriasis pills show.
Inverse psoriasis forms smooth red plaques in skin folds. What the evidence shows for steroid, nonsteroidal and systemic treatment, and which rashes look alike.
Injection-site reactions, conjunctivitis and facial redness: what the Dupixent label and phase 3 trials show, and which symptoms the label says to report.
Which acne treatments carry strong recommendations for adolescents in the 2024 American Academy of Dermatology guideline, what the trials behind them found, and where the evidence is thin.
Actinic keratosis is a precursor to squamous cell carcinoma. What the progression data show, and how fluorouracil, imiquimod, and photodynamic therapy compared in a head-to-head trial.
Why seborrheic dermatitis flares as weather cools, plus trial evidence on roflumilast foam, the first FDA-approved PDE4 inhibitor for the disease.
Baricitinib, ritlecitinib, and deuruxolitinib are FDA approved for severe alopecia areata. Compare age limits, trials, boxed warnings, and evidence gaps.
Clascoterone is an FDA-approved topical androgen receptor inhibitor for acne. See the phase 3 results, limits, adverse effects, and unanswered comparisons.
Delgocitinib cream is FDA approved for some adults with chronic hand eczema. Review the phase 3 results, label limits, safety warnings, and evidence gaps.
Lebrikizumab and nemolizumab target different atopic dermatitis pathways. Compare their FDA labels, phase 3 designs, safety limits, and evidence gaps.
Ruxolitinib cream can improve facial repigmentation in some people with nonsegmental vitiligo. Review the FDA label, trial outcomes, timeline, and risks.
Erythema nodosum causes tender red nodules on the shins and often signals an underlying trigger. What causes it, how it is diagnosed, and how it is treated.
Why lasers and energy-based devices can trigger post-inflammatory hyperpigmentation, who is most at risk, and what the evidence supports to prevent and treat it.
What solar lentigines are, how they differ from other pigmented spots, and what the evidence supports for lasers, IPL, cryotherapy, peels, and topical agents.
What randomized trials and meta-analyses show about tranexamic acid for melasma, including efficacy by route (oral, topical, injected), safety, and who should avoid it.
How clinicians tell melasma, post-inflammatory hyperpigmentation, and solar lentigines apart, why it changes treatment and prognosis, and the evidence-based options for each.
What the evidence supports for male androgenetic alopecia: minoxidil, finasteride and dutasteride, adjunct options, and realistic expectations on results and risks.
A phenotype-based guide to rosacea: how flushing, persistent redness, papules and pustules, visible vessels, and eye involvement are treated, and why trigger control matters.
How topical retinoids work, how prescription tretinoin compares with retinaldehyde, retinol, and adapalene, and how to choose a tolerable option for aging or acne-prone skin.
How clinicians classify atrophic acne scars (ice-pick, boxcar, rolling) and what the evidence supports for subcision, fractional lasers, microneedling RF, and fillers.
What the evidence supports for treating common and plantar warts, why salicylic acid and cryotherapy are first-line, and when persistent warts need a different approach.
How topical and low-dose oral minoxidil fit into female pattern hair loss treatment, with evidence on diagnosis, combination therapy, adherence, and adverse effects.
Hair loss reported with semaglutide and tirzepatide: what the evidence shows about telogen effluvium, androgenetic alopecia, diagnosis, and recovery.
Why adult-onset acne in women is often hormonally driven, how it differs from adolescent acne, and what the evidence supports for combined oral contraceptives, spironolactone, and topical therapy.
Evidence for FDA-approved hydroquinone, tretinoin and fluocinolone cream for melasma: efficacy versus monotherapy, adverse effects and adjunctive options.